Nuveen
OBX icon

Nuveen’s Obsidian Therapeutics OBX Stock Holding History

Nuveen’s Portfolio OBX Stock Details OBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.05K Buy
+209
New +$4.08K ﹤0.01% 4772

Other funds holding OBX

Alphabet Inc
Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Nuveen's OBX Position: Q3 2026 in Review

Nuveen opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 209 shares worth $3.05K. The stake represents ﹤0.01% of the portfolio and ranks #4772 among its holdings.

8 funds tracked by Wall St. Rank hold OBX as of Q3 2026.

  • Nuveen held 209 shares of Obsidian Therapeutics worth $3.05K as of Q3 2026.
  • Obsidian Therapeutics was a new Nuveen position in Q3 2026.
  • Obsidian Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q3 2026, its #4772 holding.
  • 8 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.

Based on Nuveen's 13F filing for Q3 2026, filed 10 Nov 2026.